Year: 2025

Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025

Rapid and sustained efficacy regardless of baseline IgE levels in patients with CSUHAMPTON, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) --...

Optigenex Inc. Reports Positive Results in a Group of Human Subjects with Normal Cognitive Function, in a Double-Blind, Cross Over, Placebo Controlled, Randomized Cognitive Study with ac-11(R)

Study Sponsored by Optigenex Inc. and conducted by the University of Northern Arizona led by Doctor Oneil Guthrie, demonstrates significant...

error: Content is protected !!